European Malaria Vaccine Initiative   Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2011
NCT00730782
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

fp9-pp (2 trials)

mva-pp (2 trials)

Drugs in Phase 1 Trials (5)

aluminum hydroxide (Gaviscon) (1 trial)

gla-lsq (1 trial)

gmz2 (1 trial)

pamvac (1 trial)

pfama-1-fvo[25-545] (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria (Phase 2)

Malaria, Falciparum (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 7